Novel biomarkers and psoriasis associated cardiovascular risk: a population-based study

Abstract

Abstract Background Despite the established link between psoriasis and cardiovascular risk (CVR), there remains a crucial need for improved risk stratification in this patient population.Material and Methods A descriptive cross-sectional non-controlled study was carried out on patients evaluated in the Dermatology Department of the Valencia University Clinical Hospital between 2017 and 2022. The primary endpoint of our study was to characterize patients diagnosed with moderate to severe psoriasis, focusing on their major adverse cardiovascular events (MACE) as well as new metabolic and hematological parameters, such as triglycerides to glucose (TyG) index, neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR).Results A total of 150 patients with moderate to severe psoriasis, defined by a psoriasis area severity index (PASI) > 10 during their evolution, were collected. The mean age was 50.76 years and the mean body mass index (BMI) was 28.62, defining the overweight population. Psoriatic arthritis was present in 14.7%. As CVR factors, 40.7% were smokers, 17.3% had diabetes mellitus, 24% hypertension and 30.7% dyslipidemia. As MACE, 11 acute myocardial infarction (AMI) and 1 stroke were recorded.Conclusion Novel biomarkers such has TGI, NLR or PLR hold great potential in optimizing the management and prevention of cardiovascular diseases in this vulnerable population. Our psoriasis population is similar in clinical and demographic terms, as well as in incidence of metabolic comorbidities and cardiovascular events to other series published to date.